Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Jenscare (健世科技) IPO Trading: Weak Demand and Share Concentration

Jenscare (宁波健世科技) Pre-IPO:  Massive Delays After Missing the Boat

Jenscare (宁波健世科技) Pre-IPO: Differentiated Heart Valve Portfolio

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Jenscare Scientific / Equity Capital Markets

<ul>
<li>Jenscare is a China-based medical device company with a focus on structural heart disease. The company launched a deal to  raise up to USD 30m via a Hong Kong listing.</li>
<li>In our previous note, we looked at the company's product lines and provided a brief overview on the company's valuation.</li>
<li>In this note, we provide an update for the book building. We provide our quick thoughts on the valuation and deal dynamics.</li>
</ul>


Jenscare is a China-based medical device company with a focus on structural heart disease. The company launched a deal to  raise up to USD 30m via a Hong Kong listing.
In our previous note, we looked at the company's product lines and provided a brief overview on the company's valuation.
In this note, we provide an update for the book building. We provide our quick thoughts on the valuation and deal dynamics.


Jenscare (健世科技) IPO: Candidate for Shorts